Literature DB >> 32216005

Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis.

Charline Herrscher1, Florentin Pastor1, Julien Burlaud-Gaillard1,2, Amélie Dumans1, Florian Seigneuret1, Alain Moreau1, Romuald Patient1, Sebastien Eymieux1,2, Hugues de Rocquigny1, Christophe Hourioux1,2, Philippe Roingeard1,2, Emmanuelle Blanchard1,2.   

Abstract

Hepatitis B virus (HBV) is a leading cause of cirrhosis and hepatocellular carcinoma worldwide, with 250 million individuals chronically infected. Many stages of the HBV infectious cycle have been elucidated, but the mechanisms of HBV entry remain poorly understood. The identification of the sodium taurocholate cotransporting polypeptide (NTCP) as an HBV receptor and the establishment of NTCP-overexpressing hepatoma cell lines susceptible to HBV infection opens up new possibilities for investigating these mechanisms. We used HepG2-NTCP cells, and various chemical inhibitors and RNA interference (RNAi) approaches to investigate the host cell factors involved in HBV entry. We found that HBV uptake into these cells was dependent on the actin cytoskeleton and did not involve macropinocytosis or caveolae-mediated endocytosis. Instead, entry occurred via the clathrin-mediated endocytosis pathway. HBV internalisation was inhibited by pitstop-2 treatment and RNA-mediated silencing (siRNA) of the clathrin heavy chain, adaptor protein AP-2 and dynamin-2. We were able to visualise HBV entry in clathrin-coated pits and vesicles by electron microscopy (EM) and cryo-EM with immunogold labelling. These data demonstrating that HBV uses a clathrin-mediated endocytosis pathway to enter HepG2-NTCP cells increase our understanding of the complete HBV life cycle.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  clathrin; endocytosis; hepatitis B virus; sodium taurocholate cotransporting polypeptide; viral entry

Mesh:

Substances:

Year:  2020        PMID: 32216005     DOI: 10.1111/cmi.13205

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  23 in total

Review 1.  Virus spread in the liver: mechanisms, commonalities, and unanswered questions.

Authors:  Alexi Tallan; Zongdi Feng
Journal:  Future Virol       Date:  2020-10-27       Impact factor: 1.831

Review 2.  Entry Inhibitors of Hepatitis B and D Viruses.

Authors:  Yang Yang; Youhua Xie
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  NTCP Change in Rats of Hilar Cholangiocarcinoma and Therapeutic Significance.

Authors:  Meng-Yu Zhang; Ming Luo; Kai He; Xian-Ming Xia; Jie-Ping Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters.

Authors:  Dai-Qing Wu; Qiu-Ying Ding; Na-Na Tao; Ming Tan; Yuan Zhang; Fan Li; Yu-Jiao Zhou; Mei-Ling Dong; Sheng-Tao Cheng; Fang Ren; Juan Chen; Ji-Hua Ren
Journal:  Front Microbiol       Date:  2022-05-19       Impact factor: 6.064

Review 5.  Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation.

Authors:  João Diogo Dias; Nazim Sarica; Christine Neuveut
Journal:  Viruses       Date:  2021-04-26       Impact factor: 5.048

Review 6.  Hepatitis B Virus Entry into Cells.

Authors:  Charline Herrscher; Philippe Roingeard; Emmanuelle Blanchard
Journal:  Cells       Date:  2020-06-18       Impact factor: 6.600

Review 7.  Hepatitis B virus-host interactions and novel targets for viral cure.

Authors:  Gaëtan Ligat; Eloi R Verrier; Michael Nassal; Thomas F Baumert
Journal:  Curr Opin Virol       Date:  2021-05-22       Impact factor: 7.121

Review 8.  Viral Interactions with Adaptor-Protein Complexes: A Ubiquitous Trait among Viral Species.

Authors:  Ivana Strazic Geljic; Paola Kucan Brlic; Lucija Musak; Dubravka Karner; Andreja Ambriović-Ristov; Stipan Jonjic; Peter Schu; Tihana Lenac Rovis
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 9.  Recent Advances in Hepatitis B Treatment.

Authors:  Georgia-Myrto Prifti; Dimitrios Moianos; Erofili Giannakopoulou; Vasiliki Pardali; John E Tavis; Grigoris Zoidis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-01

Review 10.  New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation.

Authors:  Alexander L Marchetti; Haitao Guo
Journal:  Cells       Date:  2020-11-06       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.